Research updates from Luvaminos
Subscribe for catalog updates, new research compounds, and quality documentation releases.
For researchers and labs. No spam — unsubscribe anytime.
Research updates from Luvaminos
Subscribe for catalog updates, new research compounds, and quality documentation releases.
For researchers and labs. No spam — unsubscribe anytime.
Signaling
A metabolically stabilized angiotensin IV–derived peptidomimetic studied as an HGF/c-Met system probe in neuronal-culture, synaptogenesis, and rodent cognitive-model research.
Reviewed by Dr. James Whitfield, PharmD · Published · Last reviewed · For research use only.
Type
Synthetic peptidomimetic (modified tripeptide-like angiotensin IV analog)
Molecular formula
C27H44N4O5
Molecular weight
~504.66 g/mol
CAS number
1401708-83-5
Fatty acid chain
N-terminal hexanoyl cap (hexanoic acid)
Sequence
N-hexanoic-Tyr-Ile-(6)aminohexanoic amide
Modification
N-terminal hexanoyl cap replacing the N-terminal residue of norleucine1-AngIV; C-terminal 6-aminohexanoic amide moiety replacing the His-Pro-Phe segment; designed to eliminate peptidase-sensitive bonds and increase metabolic stability and blood-brain-barrier permeance.
Dihexa is a peptidomimetic in the angiotensin IV (AngIV) analog class, engineered from norleucine1-angiotensin IV by retaining the Tyr-Ile pharmacophore identified as the procognitive core and replacing peptidase-labile termini with an N-terminal hexanoyl cap and a C-terminal 6-aminohexanoic amide. These modifications confer increased hydrophobicity, metabolic stability, and blood-brain-barrier permeability. Mechanistic studies proposed that Dihexa acts at the level of the hepatocyte growth factor (HGF)/c-Met receptor tyrosine kinase system — specifically at HGF dimerization and availability — with downstream readouts examined in PI3K/Akt and MAPK/ERK signaling. Historically, the parent AngIV system was associated with the AT4 binding site, later identified as insulin-regulated aminopeptidase (IRAP); the shift toward an HGF/c-Met framing is a contested element of the literature, and the key papers asserting direct HGF binding were subsequently retracted.
Lyophilized
Store dry and sealed
short term at 0–4 °C, long term at −20 °C.
Dry compound reported stable at ambient shipping temperatures for short periods. Batch molecular weight may vary with degree of hydration. For research use only.
Reviews
Hallberg M, et al. (2020). Frontiers in Pharmacology
Wright JW, Kawas LH, Harding JW. (2015). Progress in Neurobiology
Wright JW, Harding JW. (2015). Journal of Alzheimer's Disease
Reviews
Ho JK, Nation DA. (2018). Neurosci Biobehav Rev
Wright JW, Kawas LH, Harding JW. (2013). Front Endocrinol (Lausanne)
Wright JW, Harding JW. (2019). J Alzheimers Dis
Clinical
Hua X, Church K, Walker W, et al. (2022). Journal of Alzheimer's Disease
Primary research
Martino KA, Nakhre A, Demarest RM, Devilbiss DM. (2025). Neurotrauma Reports
Kawas LH, McCoy AT, Yamamoto BJ, Wright JW, Harding JW. (2025). Journal of Pharmacology and Experimental Therapeutics
Benoist CC, Kawas LH, Zhu M, et al. (2025). Journal of Pharmacology and Experimental Therapeutics
Sun X, Deng Y, Fu X, Wang S, Duan R, Zhang Y. (2021). Brain Sciences
Weiss JB, Phillips CJ, Malin EW, Gorantla VS, Harding JW, Salgar SK. (2021). Annals of Medicine and Surgery
Uribe PM, Kawas LH, Harding JW, Coffin AB. (2015). Frontiers in Cellular Neuroscience
Benoist CC, Kawas LH, Zhu M, et al. (2014). Journal of Pharmacology and Experimental Therapeutics
McCoy AT, Benoist CC, Wright JW, Kawas LH, et al. (2013). Journal of Pharmacology and Experimental Therapeutics
Kawas LH, McCoy AT, Yamamoto BJ, Wright JW, Harding JW. (2012). Journal of Pharmacology and Experimental Therapeutics
Kawas LH, Yamamoto BJ, Wright JW, Harding JW. (2011). Journal of Pharmacology and Experimental Therapeutics
Benoist CC, Wright JW, Zhu M, Appleyard SM, Wayman GA, Harding JW. (2011). Journal of Pharmacology and Experimental Therapeutics
Yamamoto BJ, Elias PD, Masino JA, et al. (2010). Journal of Pharmacology and Experimental Therapeutics
Lew RA, Mustafa T, Ye S, McDowall SG, Chai SY, Albiston AL. (2003). Journal of Neurochemistry
Albiston AL, McDowall SG, Matsacos D, et al. (2001). Journal of Biological Chemistry
Research Use Only
These products are intended for research purposes only and are not for human consumption. Not FDA approved. Not intended to diagnose, treat, cure, or prevent any disease.
| Compound | Type | Molecular weight | CAS number |
|---|---|---|---|
| DihexaThis page | Synthetic peptidomimetic (modified tripeptide-like angiotensin IV analog) | ~504.66 g/mol | 1401708-83-5 |
| PT-141 | Synthetic peptide (cyclic heptapeptide) | 1,025.18 g/mol | 189691-06-3 |
| Cardiogen | Synthetic linear tetrapeptide (short peptide bioregulator) | 489.5 g/mol | — |
| Cerebrolysin | Porcine brain-derived neuropeptide and amino-acid preparation (enzymatic hydrolysate; heterogeneous mixture) | Peptide fraction <10 kDa | 12656-61-0 |
| Cortagen | Synthetic linear tetrapeptide | 446.45 g/mol | — |
Comparison of laboratory reference specifications only. For research use only; not a therapeutic comparison.
Quality & methods